Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) | RFA DA 25 069

Frequently Asked Questions (FAQs)

What is the name of this NIH funding opportunity?

The funding opportunity is titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)" and it is offered by the National Institutes of Health (NIH).

What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number is RFA-DA-25-069.

What grant mechanism is being used?

This opportunity uses the NIH R01 grant mechanism.

Are clinical trials allowed under this R01?

No. The opportunity is explicitly designated as "Clinical Trial Not Allowed," meaning proposed studies must be mechanistic and non-clinical-trial in nature.

What is the central scientific goal of this opportunity?

The core goal is to fund mechanistic research that explains how inflammasomes contribute to central nervous system (CNS) damage when HIV infection occurs alongside acute or chronic exposure to drugs.

What topic area does this opportunity focus on in practical terms?

It centers on neuroimmune biology: how innate immune sensing complexes (inflammasomes) may drive neuroinflammation, immune dysregulation, and downstream neuropathology in the context of HIV and substance use, either independently or through synergistic effects.

What are inflammasomes in the context of this opportunity?

Within the scope of this announcement, inflammasomes are described as innate immune sensing complexes whose activation (or failure to be properly regulated) may contribute to neuroinflammation, immune dysregulation, and neurological damage in HIV and substance use contexts.

What does NIH mean by "mechanistic" research here?

Mechanistic research in this opportunity refers to studies designed to explain causal pathways and biological mechanisms: when, where, and how inflammasomes become activated (or become dysregulated), how virus-related and drug-related immune activation intersect, and how these processes contribute to CNS injury and neuropathology.

What types of interactions is NIH especially interested in?

A major emphasis is clarifying how virus-related immune activation and drug-related immune activation intersect, including whether effects are independent or synergistic in driving inflammasome activation and neuroinflammation.

What specific biological setting is emphasized?

The opportunity emphasizes mechanisms in the central nervous system (CNS), including neuroimmune populations and immune cell types within the brain that may be implicated in inflammasome-driven pathology.

Does the opportunity specify which CNS cell types should be studied?

It highlights the importance of identifying which CNS immune cell types are most implicated, including resident immune cells in the brain and other neuroimmune populations. It provides examples rather than limiting applicants to a single cell type.

Is the opportunity focused only on HIV, only on substances, or both together?

Both together. The research focus is on HIV infection occurring alongside acute or chronic exposure to drugs, and on understanding how HIV- and drug-related immune activation intersect to drive CNS outcomes.

What stages or patterns does NIH expect applicants to consider?

The announcement emphasizes mapping changes across different stages of infection, drug exposure patterns (acute or chronic), and disease trajectories, particularly as they relate to inflammasome signaling shifts and regulation.

What outcomes or complications is this research intended to help explain?

NIH is aiming for a clearer picture of inflammatory mechanisms linking HIV and substance use to neurological complications, cognitive changes, and persistent neuroinflammation.

Is biomarker development relevant to this FOA?

Yes. The opportunity explicitly discusses pinpointing molecular markers of risk and progression in people with HIV-1 who also use substances, as part of mapping inflammasome activation and dysregulation in the CNS.

What population is explicitly mentioned in relation to risk and progression markers?

People with HIV-1 who also use substances are explicitly referenced in the context of identifying molecular markers of risk and progression.

Is this opportunity intended to support therapeutic discovery work?

Yes, in a non-clinical-trial context. While clinical trials are not allowed, the research is intended to lay groundwork for future interventions by identifying actionable targets to suppress excessive inflammasome activation or modulate it more precisely.

What kinds of therapy-enabling outputs does NIH seem to expect?

Based on the description, expected outputs include target discovery, biomarker development, and preclinical rationale for future treatment approaches that could reduce neuroinflammation and correct immune dysregulation driven by HIV and drug exposure.

Does NIH want purely descriptive studies?

The description indicates NIH is not aiming for descriptive science alone. It emphasizes research that moves toward actionable targets, biomarker identification, and mechanistic explanations that support future intervention development.

What is the activity category and CFDA number listed?

The opportunity is aligned with the Education and Health activity category and lists CFDA number 93.279.

What is the award ceiling?

The listed award ceiling is $500,000.

When was this opportunity created?

The posting indicates the opportunity was created on October 29, 2024.

What is the original closing date?

The posting lists an original closing date of March 13, 2025.

Who is eligible to apply?

Eligibility is broad and includes many applicant types across government, academia, nonprofit organizations, and the private sector, as well as U.S. and non-U.S. entities.

Are state and local governments eligible?

Yes. Eligible applicants include state governments, county governments, city/township governments, and special district governments.

Are school districts eligible?

Yes. Independent school districts are listed as eligible applicants.

Are colleges and universities eligible?

Yes. Eligible applicants include public and state-controlled institutions of higher education as well as private institutions of higher education.

Are tribal entities eligible?

Yes. Eligibility includes federally recognized Native American tribal governments and tribal organizations that are not federally recognized.

Are public housing authorities eligible?

Yes. Public housing authorities and Indian housing authorities are included among eligible applicants.

Are nonprofits eligible?

Yes. Nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status are listed as eligible, with the posting specifying exclusions related to institutions of higher education within those nonprofit categories as stated.

Are for-profit organizations eligible?

Yes. For-profit organizations other than small businesses are eligible, and small businesses are also eligible.

Are U.S. territories eligible?

Yes. U.S. territories or possessions are explicitly listed among eligible applicant types.

Are foreign (non-U.S.) organizations eligible?

Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).

Are certain minority-serving institutions explicitly included?

Yes. The opportunity explicitly calls out eligibility for Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).

Are federal agencies eligible?

Yes. Eligible federal agencies are included in the eligibility list.

Are faith-based or community-based organizations eligible?

Yes. The announcement explicitly includes faith-based or community-based organizations as eligible applicants.

Are regional organizations eligible?

Yes. Regional organizations are explicitly included as eligible entities.

What kinds of research teams are likely to be a strong fit?

The opportunity is designed for teams that can connect neurobiology, immunology, HIV pathogenesis, and substance use science, with an emphasis on inflammasome-driven mechanisms in the CNS and on identifying measurable markers and modifiable targets.

What makes a project align well with NIH expectations for this FOA?

Based on the description, a strong alignment includes (1) credible mechanistic explanations of inflammasome-driven pathways in the CNS, (2) attention to the intersection of HIV- and drug-related immune activation, and (3) progress toward biomarkers and actionable targets that could support future intervention development, without proposing a clinical trial.